ChabioTech-CellinCells Collaborate on Organoid Therapeutics CDMO

CHA Biotech announced on the 18th that it has signed a contract for the contract development and manufacturing organization (CDMO) of organoid therapeutics for cartilage diseases with Cell in Cells, a company developing regenerative medicine cell therapies.

Osanghoon, CEO of Cha Biotech (left), and Jaejin Cho, CEO of Cell in Cells, are posing for a commemorative photo. [Photo by Cha Biotech]

Through this contract, CHA Biotech plans to establish a cell bank of stem cells for the development of high-quality organoid regenerative therapeutics at the pharmaceutical manufacturing facility of its subsidiary, CHA Biolabs, and provide it to Cell in Cells. This will enable Cell in Cells to accelerate the development of stem cell-derived organoid regenerative therapeutics, while CHA Biotech will gain synergy by being able to produce clinical-grade pharmaceuticals after establishing the cell bank.

Organoids refer to organ-like structures created by mimicking the characteristics of cells found in human organs and tissues. Organoids, cultured in three dimensions, are transplanted into damaged organ areas to aid in disease treatment. They are attracting attention due to their higher engraftment rates and durability compared to two-dimensional stem cell therapies, making them highly useful.

Cell in Cells possesses a pipeline of organoid regenerative therapeutics for various diseases such as skin regeneration, cartilage regeneration, and angiogenesis. The company claims to have technology capable of mass-producing uniform organoids with over 95% probability.

Osanghoon, CEO of CHA Biotech, said, “We will actively support the development of stem cell-derived organoid therapeutics promoted by Cell in Cells by utilizing the capabilities held by the CHA Biotech Group through this contract. We also expect to support U.S. clinical trials and global expansion by utilizing the cell and gene therapy CDMO facilities of our U.S. subsidiary, Matica Biotechnology.” Jo Jaejin, CEO of Cell in Cells, added, “Last year, we received the first clinical trial approval for organoid regenerative therapeutics from the Ministry of Food and Drug Safety in Korea and are currently conducting clinical trials. We plan to sequentially develop organoid regenerative therapeutics by utilizing the cell bank.”

This content was produced with the assistance of AI translation services.